CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Lymphoblastic Leukemia Clinical Trial

Official title: Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)

Status Recruiting

Clinical Trial Summary

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

Clinical Trial Description

A major obstacle to the development of effective CAR T-cells for T-cell malignancies is that the surface marker profile of malignant T-cells largely overlaps that of activated T lymphocytes. We developed a CAR T-cell approach that targets CD7, a T-cell marker highly expressed in all cases of T-cell ALL, including ETP-ALL. Its expression is also highly stable even in T-ALL cells exposed to chemotherapy. To prevent fratricide effect of the T cells, surface CD7 expression are effectively downregulated with the expression of an anti-CD7 Protein Expression Blocker (PEBL). Patients will receive anti-CD7 PEBL CART-cells. This will allow targeting the entire leukemia cell population to induce deeper and more durable remissions. ;

Related Conditions & MeSH terms

• Acute Disease
• Brain Diseases
• CAR
• Leukemia
• Leukemia, Lymphoid
• Lymphoblastic Leukemia
• Lymphoblastic Leukemia in Children
• Lymphoblastic Leukemia, Acute Adult
• Lymphoblastic Leukemia, Acute, Childhood
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Refractory Leukemia

• NCT number: NCT05043571
• Study type: Interventional
• Source: National University Hospital, Singapore
• Contact: Allen Yeoh, M.D
• Phone: +65 6772 2002
• Email: paeyej@nus.edu.sg
• Status: Recruiting
• Phase: Phase 1
• Start date: September 8, 2021
• Completion date: November 1, 2026